- Report
- August 2025
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2025
- 199 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2024
- 239 Pages
Global
From €5187EUR$6,130USD£4,350GBP
- Report
- May 2023
- 163 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- July 2024
- 150 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- October 2024
- 200 Pages
Global
From €3284EUR$3,750USD£2,851GBP
- Report
- January 2021
- 201 Pages
Global
From €3153EUR$3,600USD£2,737GBP
- Report
- September 2025
- 87 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- August 2025
- 105 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- September 2023
- 74 Pages
Global
From €3500EUR$4,281USD£3,144GBP
Menactra is a vaccine used to protect against meningococcal disease, a serious bacterial infection that can cause meningitis and other life-threatening illnesses. It is approved for use in people aged 9 months to 55 years old. The vaccine is administered as a single dose and is available in both pediatric and adult formulations.
Menactra is a part of the larger vaccine market, which includes a variety of products designed to protect against a range of infectious diseases. Vaccines are an important tool in public health, helping to reduce the spread of disease and protect vulnerable populations.
The Menactra market is highly competitive, with a number of companies offering similar products. These include Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more
